Junshi Biosciences Drug Nears EU Approval - TipRanks
| 688180 Stock | 29.36 0.77 2.56% |
About 62% of Shanghai Junshi's investor base is looking to short. The analysis of the overall investor sentiment regarding Shanghai Junshi Biosciences suggests that many traders are alarmed. The current market sentiment, together with Shanghai Junshi's historical and current headlines, can help investors time the market. In addition, many technical investors use Shanghai Junshi Bios stock news signals to limit their universe of possible portfolio assets.
Shanghai |
Junshi Biosciences Drug Nears EU Approval TipRanks
Read at news.google.com
 |
Shanghai Junshi Fundamental Analysis
We analyze Shanghai Junshi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Junshi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Junshi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Shanghai Junshi is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Shanghai Junshi Bios Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Shanghai Junshi stock to make a market-neutral strategy. Peer analysis of Shanghai Junshi could also be used in its relative valuation, which is a method of valuing Shanghai Junshi by comparing valuation metrics with similar companies.
Peers
Shanghai Junshi Related Equities
| 000506 | Zhongrun Resources | 4.97 | ||||
| 000042 | Shenzhen Centralcon | 2.12 | ||||
| 000548 | Hunan Investment | 0.18 | ||||
| 603551 | AUPU Home | 0.18 | ||||
| 002757 | Nanxing Furniture | 1.07 | ||||
| 002293 | Luolai Home | 1.22 | ||||
| 600110 | Nuode Investment | 1.35 |
Complementary Tools for Shanghai Stock analysis
When running Shanghai Junshi's price analysis, check to measure Shanghai Junshi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Junshi is operating at the current time. Most of Shanghai Junshi's value examination focuses on studying past and present price action to predict the probability of Shanghai Junshi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Junshi's price. Additionally, you may evaluate how the addition of Shanghai Junshi to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |